IN2014DN06904A - - Google Patents

Info

Publication number
IN2014DN06904A
IN2014DN06904A IN6904DEN2014A IN2014DN06904A IN 2014DN06904 A IN2014DN06904 A IN 2014DN06904A IN 6904DEN2014 A IN6904DEN2014 A IN 6904DEN2014A IN 2014DN06904 A IN2014DN06904 A IN 2014DN06904A
Authority
IN
India
Prior art keywords
ang2
ang2 binding
binding molecules
vhhs
angiogenesis
Prior art date
Application number
Inventor
Eric Borges
Andreas Gschwind
Rene Georg Ott
Marie Ange Buyse
Joachim Boucneau
Pascal Merchiers
Erik Depla
Frederik Stevenaert
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48190468&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DN06904(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of IN2014DN06904A publication Critical patent/IN2014DN06904A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Ang2 binding molecules preferably Ang2 binding immunoglobulin single variable domains like VHHs and domain antibodies pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with Ang2 mediated effects on angiogenesis. Nucleic acids encoding Ang2 binding molecules host cells and methods for preparing same.
IN6904DEN2014 2012-03-30 2013-03-27 IN2014DN06904A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12162615 2012-03-30
PCT/EP2013/056635 WO2013144266A1 (en) 2012-03-30 2013-03-27 Ang2-binding molecules

Publications (1)

Publication Number Publication Date
IN2014DN06904A true IN2014DN06904A (en) 2015-05-15

Family

ID=48190468

Family Applications (1)

Application Number Title Priority Date Filing Date
IN6904DEN2014 IN2014DN06904A (en) 2012-03-30 2013-03-27

Country Status (27)

Country Link
US (5) US20130259859A1 (en)
EP (1) EP2831111B1 (en)
JP (1) JP5970734B2 (en)
KR (1) KR102020255B1 (en)
CN (1) CN104321344B (en)
AU (1) AU2013241769B2 (en)
BR (1) BR112014023415B1 (en)
CA (1) CA2865464C (en)
CL (1) CL2014002393A1 (en)
CY (1) CY1122007T1 (en)
DK (1) DK2831111T3 (en)
EA (1) EA031182B1 (en)
ES (1) ES2729165T3 (en)
HR (1) HRP20190817T1 (en)
HU (1) HUE044263T2 (en)
IL (1) IL234234B (en)
IN (1) IN2014DN06904A (en)
LT (1) LT2831111T (en)
MX (1) MX350248B (en)
NZ (1) NZ628584A (en)
PH (1) PH12014502179B1 (en)
PL (1) PL2831111T3 (en)
PT (1) PT2831111T (en)
RS (1) RS58732B1 (en)
SI (1) SI2831111T1 (en)
TR (1) TR201908638T4 (en)
WO (1) WO2013144266A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
EP3204516B1 (en) 2014-10-06 2023-04-26 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
EP3207059A1 (en) 2014-10-17 2017-08-23 Amgen Inc. Antibodies directed to angiopoietin-1 and angiopoietin-2 for ocular therapies
SG11201706840WA (en) * 2015-03-31 2017-09-28 Vhsquared Ltd Peptide construct having a protease-cleavable linker
EP3328886B1 (en) 2015-07-29 2020-09-16 Allergan, Inc. Heavy chain only antibodies to ang-2
CN110088136A (en) * 2016-10-13 2019-08-02 达纳-法伯癌症研究所有限公司 Use the composition and method in gene expression signature prediction melanoma for the CTLA4 response blocked and drug resistance
KR102143132B1 (en) * 2016-12-26 2020-08-10 기초과학연구원 Composition for Preventing or Treating of Ocular Diseases Comprising Anti-Ang2 Antibody
EP3565839A4 (en) 2017-01-05 2021-04-21 Gensun Biopharma Inc. CHECKPOINT REGULATOR ANTAGONISTS
JP2020521797A (en) * 2017-06-02 2020-07-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Anti-cancer drug combination therapy
CN108659130B (en) * 2018-05-28 2021-09-10 长春力太生物技术有限公司 Anti-carcinoembryonic antigen nano antibody and application thereof
JP2021532170A (en) 2018-06-29 2021-11-25 ジェンサン バイオファーマ、 インコーポレイテッドGensun Biopharma, Inc. Trispecific antagonist
US20220204603A1 (en) * 2019-02-25 2022-06-30 Pharmabcine Inc. Anti-ang2 antibody and use thereof
US20220185875A1 (en) * 2019-03-18 2022-06-16 Jiangsu Hengrui Medicine Co., Ltd. Bispecific antibody specifically bound to vegf and ang2
US10851157B2 (en) 2019-07-01 2020-12-01 Gensun Biopharma, Inc. Antagonists targeting the TGF-β pathway
CA3168939A1 (en) * 2020-03-03 2021-09-10 Aptitude Medical Systems, Inc. Aptamers and use thereof
CN111875706B (en) * 2020-07-16 2021-03-30 广州康盛生物科技股份有限公司 Single-domain antibody of anti-human IgE protein and application thereof
US20220389120A1 (en) 2021-06-03 2022-12-08 Gensun Biopharma Inc. Multispecific antagonists
MX2024002962A (en) * 2021-09-10 2024-05-17 Soter Biopharma Pte Ltd ANTI-ANG2 ANTIBODY, METHOD OF PREPARATION AND APPLICATION OF THE SAME.
WO2024065268A1 (en) 2022-09-28 2024-04-04 科兴生物制药股份有限公司 Antibody or antigen-binding fragment capable of identifying ang-2, and bispecific antibody for simultaneously identifying vegf and ang-2
CN115819592A (en) * 2022-12-27 2023-03-21 上海医药集团生物治疗技术有限公司 ROR 1-targeted antigen binding proteins
WO2025117641A2 (en) * 2023-12-01 2025-06-05 Tavotek Biotherapeutics (Hong Kong) Limited ANTIBODIES TARGETING DISEASE ASSOCIATED ANTIGEN AND γδ T CELL RECEPTORS AND USES THEREOF
WO2025137089A1 (en) * 2023-12-19 2025-06-26 Beam Therapeutics Inc. Cd19-binding polypeptides, compositions comprising the same, and methods for use thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE452975T1 (en) 1992-08-21 2010-01-15 Univ Bruxelles IMMUNOGLOBULINS WITHOUT LIGHT CHAINS
US5643755A (en) 1994-10-07 1997-07-01 Regeneron Pharmaceuticals Inc. Nucleic acid encoding tie-2 ligand
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
CN101684158A (en) 2001-01-17 2010-03-31 特鲁比昂药品公司 Binding domain-immunoglobulin fusion proteins
EP1399484B1 (en) 2001-06-28 2010-08-11 Domantis Limited Dual-specific ligand and its use
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
BRPI0316092B8 (en) 2002-11-08 2021-05-25 Ablynx Nv single domain antibodies directed against tumor necrosis factor alpha and uses for them
JP2006519763A (en) 2002-11-08 2006-08-31 アブリンクス エン．ヴェー． Method of administering therapeutic polypeptides and polypeptides therefor
EP2251357A1 (en) 2003-11-07 2010-11-17 Ablynx N.V. Camelidae single domain antibodies VHH directed against epidermal growth factor receptor and uses therefor
US20050284249A1 (en) 2004-06-29 2005-12-29 Arnone David F Worm type gear mover assembly
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
KR101017301B1 (en) 2004-12-21 2011-02-28 메드임뮨 리미티드 Antibodies to Angiopoietin-2 and Uses thereof
RU2464276C2 (en) 2005-05-18 2012-10-20 Аблинкс Н.В. Improved nanobodies against tumour necrosis factor-alpha
US20080014196A1 (en) 2006-06-06 2008-01-17 Genentech, Inc. Compositions and methods for modulating vascular development
EP2057191A1 (en) 2006-08-18 2009-05-13 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
CA2678218A1 (en) 2007-02-21 2008-08-28 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
DE112009000507T5 (en) 2008-03-05 2011-02-10 Ablynx Nv Novel antigen-binding dimer complexes, process for their preparation and their use
DK2285408T3 (en) * 2008-06-05 2019-02-04 Ablynx Nv AMINO ACID SEQUENCES AGAINST COATING PROTEINS IN A VIRUS AND POLYPEPTIDES INCLUDING THESE FOR TREATMENT OF VIRUSAL DISEASES
US8858940B2 (en) * 2008-12-10 2014-10-14 Ablynx N.V. Amino acid sequences directed against the Angiopoietin/Tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis
JO3182B1 (en) 2009-07-29 2018-03-08 Regeneron Pharma Human antibiotics with high pH generation - 2
US20130078247A1 (en) * 2011-04-01 2013-03-28 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to dii4 and ang2
US9527925B2 (en) * 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2

Also Published As

Publication number Publication date
US20230203146A1 (en) 2023-06-29
JP5970734B2 (en) 2016-08-17
US20170107281A1 (en) 2017-04-20
HRP20190817T1 (en) 2019-06-28
EA201401065A1 (en) 2015-03-31
CL2014002393A1 (en) 2015-01-23
BR112014023415B1 (en) 2022-04-12
PH12014502179A1 (en) 2014-12-10
CN104321344B (en) 2017-11-21
RS58732B1 (en) 2019-06-28
SI2831111T1 (en) 2019-06-28
KR102020255B1 (en) 2019-09-10
AU2013241769A1 (en) 2014-08-28
US20200207845A1 (en) 2020-07-02
PL2831111T3 (en) 2019-09-30
TR201908638T4 (en) 2019-07-22
US20130259859A1 (en) 2013-10-03
PH12014502179B1 (en) 2014-12-10
NZ628584A (en) 2016-04-29
CY1122007T1 (en) 2020-10-14
IL234234B (en) 2020-06-30
DK2831111T3 (en) 2019-04-29
CN104321344A (en) 2015-01-28
BR112014023415A2 (en) 2017-07-11
JP2015516805A (en) 2015-06-18
EP2831111B1 (en) 2019-03-20
EA031182B1 (en) 2018-11-30
AU2013241769B2 (en) 2017-05-11
WO2013144266A1 (en) 2013-10-03
CA2865464C (en) 2022-07-12
HUE044263T2 (en) 2019-10-28
EP2831111A1 (en) 2015-02-04
US20190135907A1 (en) 2019-05-09
LT2831111T (en) 2019-05-10
MX350248B (en) 2017-08-31
ES2729165T3 (en) 2019-10-30
MX2014011171A (en) 2015-03-06
PT2831111T (en) 2019-05-31
CA2865464A1 (en) 2013-10-03
KR20140146606A (en) 2014-12-26

Similar Documents

Publication Publication Date Title
IN2014DN06904A (en)
TN2013000390A1 (en) Bispecific binding molecules binding to vegf and ang2
PH12013500410B1 (en) Vegf-binding molecules
TN2012000144A1 (en) Dll4-binding molecules
SA518400424B1 (en) Antibody molecules for cancer treatment
TN2012000145A1 (en) Bispecific binding molecules for anti-angiogenesis therapy
TN2013000389A1 (en) BISPECIFIC BINDING MOLECULES BINDING TO Dll4 AND Ang2
PH12012501838A1 (en) Aptamers to ãŸ-ngf and their use in treating ãŸ-ngf mediated diseases and disorders
WO2015109124A3 (en) Immunomodulatory agents
ZA201405021B (en) Cx3cr1-binding polypeptides
HUE054115T2 (en) Novel antigen binding proteins and their use as addressing product for the treatment of cancer